<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344759</url>
  </required_header>
  <id_info>
    <org_study_id>CCHMC 2009-0514</org_study_id>
    <nct_id>NCT01344759</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea</brief_title>
  <official_title>Effect of Increasing Depth of Dexmedetomidine and Propofol Anesthesia on Upper Airway Morphology in Children With History of Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to examine the effects of two commonly used anesthetic
      drugs, dexmedetomidine and propofol, have on the shape and muscle tone of the upper airway in
      children, adolescents, and young adults with a history of obstructive sleep apnea (OSA)
      having an MRI scan.

      The results of this study will help in making the best decisions regarding the anesthesia
      medications that are most appropriate for children, adolescents, and young adults with OSA
      during MRI studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with OSA are at risk for airway obstruction (a condition that makes it difficult to
      breath) during sedation and anesthesia. Dexmedetomidine and propofol are safe and effective
      drugs regularly used by anesthesiologists. These drugs are used to put patients to sleep for
      operations and certain studies like MRI scans. However, there have been no studies describing
      the effects these drugs have on the upper airway of children, adolescents, and young adults
      with OSA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cross Sectional Area of the Pharyngeal Airway</measure>
    <time_frame>during MRI within first 10 minutes of scanning</time_frame>
    <description>The primary outcome measures will be the cross sectional area of the pharyngeal airway of the patients measured at two levels soft palate (nasopharyngeal) and base of the tongue (retroglossal). Magnetic resonance images of the airway were obtained during low (1 mcg/kg/hr) and high (3 mcg/kg/hr) doses of DEX or low (100 mcg/kg/m) and high (200 mcg/kg/m) doses of Propofol. All were administered through an intravenous (IV) catheter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obstructive Index Until Recovery Room Discharge</measure>
    <time_frame>During MRI and until recovery room discharge - approximately 30-250 minutes</time_frame>
    <description>The Obstructive Index is a count of the obstructive apnea events per hour of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Disturbance Index</measure>
    <time_frame>During MRI and until recovery room discharge - approximately 30-250 minutes</time_frame>
    <description>The respiratory disturbance index is a count of respiratory disturbance events per hour of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needed Artificial Airway</measure>
    <time_frame>During MRI and until recovery room discharge - approximately 30-250 minutes</time_frame>
    <description>This is the count of the number of patients who needed an artificial airway.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Room Air SpO2</measure>
    <time_frame>During MRI and until recovery room discharge - approximately 30-250 minutes</time_frame>
    <description>The patient's oxygen saturation on room air.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with documented history of OSA by polysomnography who require anesthesia for
             MRI sleep study or MRI brain imaging study.

          2. Subjects must be 12 months to 25 years of age (inclusive)

          3. Either the subject (if subject's age is 18-25) or the subject's legally authorized
             representative has given written informed consent to participate in the study

        Exclusion Criteria:

          1. The subject has life-threatening medical conditions (American Society of
             Anesthesiologists Physical Status 4, 5 or 6). The American Society of
             Anesthesiologists (ASA) classification scale is a measure of physical status or how
             healthy the patient is. For our study, we will focus on children which are defined as
             ASA I, II or III which means a healthy child (ASA I), a child with a systemic disease
             that is mild and well controlled (ASA II) or a child with systemic disease that is
             severe and controlled (ASA III).

          2. The subject is allergic to or has a contraindication to propofol or dexmedetomidine.

          3. The subject has a tracheostomy or other mechanical airway device

          4. The subject is not scheduled to receive anesthesia-sedation care for the MRI

          5. The subject has a history or a family (parent or sibling) history of malignant
             hyperthermia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Mahmoud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mason KP, Zgleszewski SE, Dearden JL, Dumont RS, Pirich MA, Stark CD, D'Angelo P, Macpherson S, Fontaine PJ, Connor L, Zurakowski D. Dexmedetomidine for pediatric sedation for computed tomography imaging studies. Anesth Analg. 2006 Jul;103(1):57-62, table of contents.</citation>
    <PMID>16790626</PMID>
  </reference>
  <reference>
    <citation>Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000 Aug;93(2):382-94.</citation>
    <PMID>10910487</PMID>
  </reference>
  <reference>
    <citation>Talke P, Lobo E, Brown R. Systemically administered alpha2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology. 2003 Jul;99(1):65-70.</citation>
    <PMID>12826844</PMID>
  </reference>
  <reference>
    <citation>Talke P, Richardson CA, Scheinin M, Fisher DM. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg. 1997 Nov;85(5):1136-42.</citation>
    <PMID>9356115</PMID>
  </reference>
  <reference>
    <citation>Doze VA, Chen BX, Maze M. Dexmedetomidine produces a hypnotic-anesthetic action in rats via activation of central alpha-2 adrenoceptors. Anesthesiology. 1989 Jul;71(1):75-9.</citation>
    <PMID>2568769</PMID>
  </reference>
  <reference>
    <citation>Drummond GB. Comparison of sedation with midazolam and ketamine: effects on airway muscle activity. Br J Anaesth. 1996 May;76(5):663-7.</citation>
    <PMID>8688266</PMID>
  </reference>
  <reference>
    <citation>Drummond GB. Influence of thiopentone on upper airway muscles. Br J Anaesth. 1989 Jul;63(1):12-21.</citation>
    <PMID>2765337</PMID>
  </reference>
  <reference>
    <citation>Hwang JC, St John WM, Bartlett D Jr. Respiratory-related hypoglossal nerve activity: influence of anesthetics. J Appl Physiol Respir Environ Exerc Physiol. 1983 Sep;55(3):785-92.</citation>
    <PMID>6629915</PMID>
  </reference>
  <reference>
    <citation>Hudgel DW, Harasick T, Katz RL, Witt WJ, Abelson TI. Uvulopalatopharyngoplasty in obstructive apnea. Value of preoperative localization of site of upper airway narrowing during sleep. Am Rev Respir Dis. 1991 May;143(5 Pt 1):942-6.</citation>
    <PMID>2024847</PMID>
  </reference>
  <reference>
    <citation>Nandi PR, Charlesworth CH, Taylor SJ, Nunn JF, Doré CJ. Effect of general anaesthesia on the pharynx. Br J Anaesth. 1991 Feb;66(2):157-62.</citation>
    <PMID>1817614</PMID>
  </reference>
  <reference>
    <citation>SAFAR P, ESCARRAGA LA, CHANG F. Upper airway obstruction in the unconscious patient. J Appl Physiol. 1959 Sep;14:760-4.</citation>
    <PMID>14440737</PMID>
  </reference>
  <reference>
    <citation>Litman RS, Kottra JA, Berkowitz RJ, Ward DS. Upper airway obstruction during midazolam/nitrous oxide sedation in children with enlarged tonsils. Pediatr Dent. 1998 Sep-Oct;20(5):318-20.</citation>
    <PMID>9803430</PMID>
  </reference>
  <reference>
    <citation>Donnelly LF, Casper KA, Chen B, Koch BL. Defining normal upper airway motion in asymptomatic children during sleep by means of cine MR techniques. Radiology. 2002 Apr;223(1):176-80.</citation>
    <PMID>11930064</PMID>
  </reference>
  <reference>
    <citation>Donnelly LF, Shott SR, LaRose CR, Chini BA, Amin RS. Causes of persistent obstructive sleep apnea despite previous tonsillectomy and adenoidectomy in children with down syndrome as depicted on static and dynamic cine MRI. AJR Am J Roentgenol. 2004 Jul;183(1):175-81.</citation>
    <PMID>15208134</PMID>
  </reference>
  <reference>
    <citation>Ibacache ME, Muñoz HR, Brandes V, Morales AL. Single-dose dexmedetomidine reduces agitation after sevoflurane anesthesia in children. Anesth Analg. 2004 Jan;98(1):60-3, table of contents.</citation>
    <PMID>14693585</PMID>
  </reference>
  <reference>
    <citation>Guler G, Akin A, Tosun Z, Ors S, Esmaoglu A, Boyaci A. Single-dose dexmedetomidine reduces agitation and provides smooth extubation after pediatric adenotonsillectomy. Paediatr Anaesth. 2005 Sep;15(9):762-6.</citation>
    <PMID>16101707</PMID>
  </reference>
  <reference>
    <citation>Petroz GC, Sikich N, James M, van Dyk H, Shafer SL, Schily M, Lerman J. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology. 2006 Dec;105(6):1098-110.</citation>
    <PMID>17122572</PMID>
  </reference>
  <reference>
    <citation>Mahmoud M, Tyler T, Sadhasivam S. Dexmedetomidine and ketamine for large anterior mediastinal mass biopsy. Paediatr Anaesth. 2008 Oct;18(10):1011-3. doi: 10.1111/j.1460-9592.2008.02604.x.</citation>
    <PMID>18811855</PMID>
  </reference>
  <reference>
    <citation>Eastwood PR, Platt PR, Shepherd K, Maddison K, Hillman DR. Collapsibility of the upper airway at different concentrations of propofol anesthesia. Anesthesiology. 2005 Sep;103(3):470-7.</citation>
    <PMID>16129969</PMID>
  </reference>
  <reference>
    <citation>Mason KP, Zurakowski D, Zgleszewski SE, Robson CD, Carrier M, Hickey PR, Dinardo JA. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth. 2008 May;18(5):403-11. doi: 10.1111/j.1460-9592.2008.02468.x. Epub 2008 Mar 18.</citation>
    <PMID>18363626</PMID>
  </reference>
  <reference>
    <citation>Mason KP, Zgleszewski SE, Prescilla R, Fontaine PJ, Zurakowski D. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Paediatr Anaesth. 2008 May;18(5):393-402. doi: 10.1111/j.1460-9592.2008.02451.x. Epub 2008 Mar 18.</citation>
    <PMID>18363628</PMID>
  </reference>
  <reference>
    <citation>Koroglu A, Teksan H, Sagir O, Yucel A, Toprak HI, Ersoy OM. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesth Analg. 2006 Jul;103(1):63-7, table of contents.</citation>
    <PMID>16790627</PMID>
  </reference>
  <reference>
    <citation>Usher AG, Kearney RA, Tsui BC. Propofol total intravenous anesthesia for MRI in children. Paediatr Anaesth. 2005 Jan;15(1):23-8.</citation>
    <PMID>15649159</PMID>
  </reference>
  <reference>
    <citation>Frankville DD, Spear RM, Dyck JB. The dose of propofol required to prevent children from moving during magnetic resonance imaging. Anesthesiology. 1993 Nov;79(5):953-8.</citation>
    <PMID>8239013</PMID>
  </reference>
  <reference>
    <citation>Levati A, Colombo N, Arosio EM, Savoia G, Tommasino C, Scialfa G, Boselli L. Propofol anaesthesia in spontaneously breathing paediatric patients during magnetic resonance imaging. Acta Anaesthesiol Scand. 1996 May;40(5):561-5.</citation>
    <PMID>8792885</PMID>
  </reference>
  <reference>
    <citation>Evans RG, Crawford MW, Noseworthy MD, Yoo SJ. Effect of increasing depth of propofol anesthesia on upper airway configuration in children. Anesthesiology. 2003 Sep;99(3):596-602.</citation>
    <PMID>12960543</PMID>
  </reference>
  <reference>
    <citation>Litman RS, Weissend EE, Shrier DA, Ward DS. Morphologic changes in the upper airway of children during awakening from propofol administration. Anesthesiology. 2002 Mar;96(3):607-11.</citation>
    <PMID>11873035</PMID>
  </reference>
  <reference>
    <citation>Mathru M, Esch O, Lang J, Herbert ME, Chaljub G, Goodacre B, vanSonnenberg E. Magnetic resonance imaging of the upper airway. Effects of propofol anesthesia and nasal continuous positive airway pressure in humans. Anesthesiology. 1996 Feb;84(2):273-9.</citation>
    <PMID>8602656</PMID>
  </reference>
  <reference>
    <citation>Thompson JR, Schneider S, Ashwal S, Holden BS, Hinshaw DB Jr, Hasso AN. The choice of sedation for computed tomography in children: a prospective evaluation. Radiology. 1982 May;143(2):475-9.</citation>
    <PMID>7071350</PMID>
  </reference>
  <reference>
    <citation>Napoli KL, Ingall CG, Martin GR. Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography. J Pediatr. 1996 Aug;129(2):287-91.</citation>
    <PMID>8765629</PMID>
  </reference>
  <reference>
    <citation>Greenberg SB, Faerber EN, Aspinall CL, Adams RC. High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age. AJR Am J Roentgenol. 1993 Sep;161(3):639-41.</citation>
    <PMID>8352124</PMID>
  </reference>
  <reference>
    <citation>Ronchera-Oms CL, Casillas C, Martí-Bonmatí L, Poyatos C, Tomás J, Sobejano A, Jiménez NV. Oral chloral hydrate provides effective and safe sedation in paediatric magnetic resonance imaging. J Clin Pharm Ther. 1994 Aug;19(4):239-43.</citation>
    <PMID>7989402</PMID>
  </reference>
  <reference>
    <citation>Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000 Mar;90(3):699-705.</citation>
    <PMID>10702460</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <results_first_submitted>August 20, 2015</results_first_submitted>
  <results_first_submitted_qc>January 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2016</results_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>MRI</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Propofol</keyword>
  <keyword>Anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Propofol</title>
          <description>Propofol: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28">Two of the original DEX group subjects were removed, due to receiving dexmedetomidine and propofol.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients failed to reach sedation level</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propofol</title>
          <description>Propofol: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" lower_limit="5.8" upper_limit="14.3"/>
                    <measurement group_id="B2" value="8.3" lower_limit="4.7" upper_limit="16.1"/>
                    <measurement group_id="B3" value="8.6" lower_limit="5.3" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cross Sectional Area of the Pharyngeal Airway</title>
        <description>The primary outcome measures will be the cross sectional area of the pharyngeal airway of the patients measured at two levels soft palate (nasopharyngeal) and base of the tongue (retroglossal). Magnetic resonance images of the airway were obtained during low (1 mcg/kg/hr) and high (3 mcg/kg/hr) doses of DEX or low (100 mcg/kg/m) and high (200 mcg/kg/m) doses of Propofol. All were administered through an intravenous (IV) catheter.</description>
        <time_frame>during MRI within first 10 minutes of scanning</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump (Low dose). Baseline airway images are obtained during this time.
If a subject moves during baseline images a bolus of Propofol 0.5 mcg/kg will be given over 10 seconds and infusion rate will be increased to 120 mcg/kg/hr. If the subject moves a second time the research study will be terminated and patient will be under care of clinical team.
After the initial set of airway images are obtained, a bolus dose of propofol 2 mcg/kg will be given over 2 minutes followed by an increase in the infusion rate to 200 mcg/kg/hr (high dose).</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump (low dose). Baseline airway images are obtained during this time.
If a subject moves during baseline images a bolus of DEX 0.5 mcg/kg will be given over 3 minutes and infusion rate will be increased to 1.5 mcg/kg/hr. If the subject moves a second time the research study will be terminated and patient will be under care of clinical team.
After the initial set of airway images are obtained, a 2 mcg/kg bolus of DEX will be given over 10 minutes followed by an increase in the infusion rate to 3 mcg/kg/hr (high dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Cross Sectional Area of the Pharyngeal Airway</title>
          <description>The primary outcome measures will be the cross sectional area of the pharyngeal airway of the patients measured at two levels soft palate (nasopharyngeal) and base of the tongue (retroglossal). Magnetic resonance images of the airway were obtained during low (1 mcg/kg/hr) and high (3 mcg/kg/hr) doses of DEX or low (100 mcg/kg/m) and high (200 mcg/kg/m) doses of Propofol. All were administered through an intravenous (IV) catheter.</description>
          <units>mm^2</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Dose Sedative, Nasopharyngeal measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.9" lower_limit="185.4" upper_limit="267.2"/>
                    <measurement group_id="O2" value="178.5" lower_limit="148.5" upper_limit="222.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Dose Sedative, Nasopharyngeal measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.6" lower_limit="148.9" upper_limit="291.7"/>
                    <measurement group_id="O2" value="235.4" lower_limit="145.0" upper_limit="258.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Dose Sedative, Retroglossal measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.1" lower_limit="67.8" upper_limit="167.0"/>
                    <measurement group_id="O2" value="120.9" lower_limit="63.6" upper_limit="179.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose sedative, Retroglossal measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.1" lower_limit="53.6" upper_limit="134.4"/>
                    <measurement group_id="O2" value="120.5" lower_limit="50.1" upper_limit="178.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Obstructive Index Until Recovery Room Discharge</title>
        <description>The Obstructive Index is a count of the obstructive apnea events per hour of sleep</description>
        <time_frame>During MRI and until recovery room discharge - approximately 30-250 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O2">
            <title>Mild OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
          <group group_id="O3">
            <title>Moderate OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O4">
            <title>Moderate OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
          <group group_id="O5">
            <title>Severe OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O6">
            <title>Severe OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
        </group_list>
        <measure>
          <title>Obstructive Index Until Recovery Room Discharge</title>
          <description>The Obstructive Index is a count of the obstructive apnea events per hour of sleep</description>
          <units>Apnea events/hour of sleep</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.4" upper_limit="4.9"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.3" upper_limit="3.5"/>
                    <measurement group_id="O3" value="8.0" lower_limit="7.4" upper_limit="8.6"/>
                    <measurement group_id="O4" value="8.0" lower_limit="5.9" upper_limit="8.9"/>
                    <measurement group_id="O5" value="16.7" lower_limit="14.1" upper_limit="23.3"/>
                    <measurement group_id="O6" value="17.1" lower_limit="14.6" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Disturbance Index</title>
        <description>The respiratory disturbance index is a count of respiratory disturbance events per hour of sleep.</description>
        <time_frame>During MRI and until recovery room discharge - approximately 30-250 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O2">
            <title>Mild OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
          <group group_id="O3">
            <title>Moderate OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O4">
            <title>Moderate OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
          <group group_id="O5">
            <title>Severe OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O6">
            <title>Severe OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Disturbance Index</title>
          <description>The respiratory disturbance index is a count of respiratory disturbance events per hour of sleep.</description>
          <units>respir.disturbance events/hr of sleep</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.8" upper_limit="5.4"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.4" upper_limit="4.1"/>
                    <measurement group_id="O3" value="8.8" lower_limit="7.7" upper_limit="9.8"/>
                    <measurement group_id="O4" value="7.1" lower_limit="5.9" upper_limit="9.1"/>
                    <measurement group_id="O5" value="16.6" lower_limit="14.3" upper_limit="19.6"/>
                    <measurement group_id="O6" value="25.2" lower_limit="14.7" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Needed Artificial Airway</title>
        <description>This is the count of the number of patients who needed an artificial airway.</description>
        <time_frame>During MRI and until recovery room discharge - approximately 30-250 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O2">
            <title>Mild OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
          <group group_id="O3">
            <title>Moderate OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O4">
            <title>Moderate OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
          <group group_id="O5">
            <title>Severe OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O6">
            <title>Severe OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
        </group_list>
        <measure>
          <title>Needed Artificial Airway</title>
          <description>This is the count of the number of patients who needed an artificial airway.</description>
          <units>Number of artifical airway events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Room Air SpO2</title>
        <description>The patient's oxygen saturation on room air.</description>
        <time_frame>During MRI and until recovery room discharge - approximately 30-250 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O2">
            <title>Mild OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
          <group group_id="O3">
            <title>Moderate OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O4">
            <title>Moderate OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
          <group group_id="O5">
            <title>Severe OSA and Dexmedetomidine</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive DEX.</description>
          </group>
          <group group_id="O6">
            <title>Severe OSA and Propofol</title>
            <description>Patients were stratified by OSA severity as documented on the patient's sleep study report: mild, moderate, or severe. (Mild=obstructive index 1-5, Moderate= obstructive index &gt;5-10, Severe=obstructive index&gt;10)
Additionally this patient was assigned to receive Propofol.</description>
          </group>
        </group_list>
        <measure>
          <title>Room Air SpO2</title>
          <description>The patient's oxygen saturation on room air.</description>
          <units>percentage of SpO2</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" lower_limit="86.7" upper_limit="87.7"/>
                    <measurement group_id="O2" value="88.0" lower_limit="83.0" upper_limit="91.0"/>
                    <measurement group_id="O3" value="86.3" lower_limit="84.8" upper_limit="87.5"/>
                    <measurement group_id="O4" value="89.0" lower_limit="87.0" upper_limit="93.0"/>
                    <measurement group_id="O5" value="84.0" lower_limit="77.0" upper_limit="88.8"/>
                    <measurement group_id="O6" value="88.0" lower_limit="80.4" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Propofol</title>
          <description>Propofol: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Failure to standardize mouth opening, due to stimulation of the subject during manipulation of the mouth No baseline measurements were obtained while awake Many patients had Downs syndrome so the results may not apply across all patients with OSA</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mohamed Mahmoud</name_or_title>
      <organization>Cincinnati Children's Hosptial Medical Center</organization>
      <phone>513-636-4408</phone>
      <email>Mohamed.Mahmoud@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

